Member Info for Jelenko

What can Trump do to reduce POO. Not much in my view except empty the SPR and I'm not sure there will be many takers, there have been complaints from customers that it contained too much sulphur. Yes Oil is a good way for Russia to hurt USA if they want. We are used to high oil prices.

Saur, you are cantankerous, were you born in the 40's by any chance?

Maxie, Yes, you are correct. Not sure why I thought it was illumina. Menarini-silicon biosystems bought cellsearch April 2017

Cellsearch has been acquired by illumina a while back.

Scoutlouie Angle apparently refused to talk to a prospective bidder around 3 yrs ago, the bid was too low ball AN said. The press at the time said the bid was �2. Given where we are now I suspect any offer below �5 would not be taken seriously. Some people claim that in a private chat with the FD a starting point of �20 was mentioned. That would be nice. I, myself struggle to see who would buy the company when they will likely be able to buy a license to use Parsortix, or buy the machines required at much less cost.

Shirley, Totally agree with you. This share is very frustrating. Market makers take advantage which is why it drops after any jump that is not driven by financial news. I would say that Dermot Keane would not have invested millions of his own money for no reason. I also look at Exact Sciences, listed on Nazdaq. They have one application that is FDA approved and are valued at $5b. I can't understand that myself. The read across to AGL is about �30 per share. That is for one application that is lab based and therefore growth restricted. We will have numerous FDA approved applications in, I suspect a couple of years time. We have an amazing growth potential especially with the new downstream tool bolted on. Some people say that we will be taken out on FDA approval, I don't know really. But the �2, equating to �234m market cap seems a tad light compared to Exact Sciences. I do know that the compny uses them as an example of what can be achieved.

Yes, it's taken a while but finally Parsortix is demonstrating things that we shareholders already believed were possible. If we were listed on Nazdaq, this news alone would multibag our sp. AIM and UK markets are useless really. When this is briefed if we get a 1-2p move and increased spread to boot, that will be it I think. The real turning point will be FDA, maybe 6-7 months away. Surely then even on AIM we will hit the dizzy heights of �2!! Of course if we were USA listed (not OTC) it would likely be �10 on FDA approval.

This is the more detailed news of the study that was completed in the summer. Regarding FDA, they will be applying for Metastatic Breast cancer first, after the present clinical trial lead by MD Anderson is concluded, (June/July) Once FDA is gained for that(Dec/Jan) they will be applying for Ovarian on a 510K basis ( this should be quick) this will not need any further clinical trials beyond the next one that was mentioned in today's release.

I don't see anything new in this article/presentation that we weren't briefed on last July.

I have been invested for several years, I have to say they have not been leakey in my view. We don't ask for reasons when the sp falls day after day. If there is an RNS great, but I suspect it's the ebb and flow of the stock market and nothing more. I can see the upward momentum now through to FDA approval.

Hi, As I have already posted on the other board, I have been in contact with Oncolab and AGL both have confirmed that Oncolab are using Parsortix.